The link between T cell activation and development of functionally useful tumour-associated high endothelial venules.
T-cell activation
high endothelial venules
immune checkpoint blockade
lymphotoxin-β receptor agonist
Journal
Discovery immunology
ISSN: 2754-2483
Titre abrégé: Discov Immunol
Pays: England
ID NLM: 9918486782306676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
02
2023
revised:
28
03
2023
accepted:
24
04
2023
medline:
8
6
2023
pubmed:
8
6
2023
entrez:
8
6
2023
Statut:
epublish
Résumé
High endothelial venules (HEVs) are specialized postcapillary venules that specifically serve to recruit circulating lymphocytes to secondary lymphoid organs (SLOs) where cognate antigens can be encountered, and immune responses can be initiated. The presence of HEV-like vessels in primary human solid tumours and their association with lymphocyte infiltration and favourable clinical outcomes and response to immunotherapy have provided a rationale for therapeutically inducing these vessels in tumours for immunotherapeutic benefit. Here we specifically discuss evidence for a link between T-cell activation and development of useful tumour-associated HEV (TA-HEV). We discuss the molecular and functional features of TA-HEV, highlighting the benefits for promoting tumour immunity and the important unanswered questions that need to be addressed before TA-HEV induction can be optimized for immunotherapeutic benefit.
Identifiants
pubmed: 37287625
doi: 10.1093/discim/kyad006
pii: kyad006
pmc: PMC10243744
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
kyad006Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology.
Déclaration de conflit d'intérêts
Not applicable.
Références
Cancer Cell. 2022 Mar 14;40(3):318-334.e9
pubmed: 35120598
Cancer Res. 2012 Nov 1;72(21):5473-82
pubmed: 22962270
Nat Immunol. 2004 Feb;5(2):141-9
pubmed: 14704792
Microcirculation. 1996 Sep;3(3):287-300
pubmed: 8930886
Elife. 2020 Jan 28;9:
pubmed: 31990272
Cell Rep. 2020 Jan 21;30(3):714-724.e5
pubmed: 31968248
Cancer Res. 2006 Oct 1;66(19):9617-24
pubmed: 17018619
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
Br J Cancer. 2019 Aug;121(5):395-404
pubmed: 31358939
J Clin Invest. 1996 Jan 1;97(1):54-64
pubmed: 8550850
Cancer Immunol Immunother. 2008 Jan;57(1):85-95
pubmed: 17605009
Nat Commun. 2020 Jul 30;11(1):3798
pubmed: 32732867
Adv Anat Embryol Cell Biol. 2014;214:81-91
pubmed: 24276888
Nat Immunol. 2017 Nov;18(11):1207-1217
pubmed: 28892469
Annu Rev Immunol. 2005;23:787-819
pubmed: 15771586
Nature. 2011 Nov 13;479(7374):542-6
pubmed: 22080953
Angiogenesis. 2021 Nov;24(4):719-753
pubmed: 33956259
Mod Pathol. 2018 Jun;31(6):910-922
pubmed: 29416107
J Clin Med. 2020 Aug 13;9(8):
pubmed: 32823631
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Cell. 2020 Oct 15;183(2):347-362.e24
pubmed: 33064988
Cancer Cell. 2016 Mar 14;29(3):285-296
pubmed: 26977880
J Immunol. 2004 Nov 15;173(10):6161-8
pubmed: 15528353
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404866
Immunol Rev. 2009 May;229(1):232-43
pubmed: 19426225
Cell Rep. 2019 Mar 12;26(11):3116-3131.e5
pubmed: 30865898
Immunity. 2016 Oct 18;45(4):877-888
pubmed: 27760341
Nat Commun. 2015 May 13;6:7114
pubmed: 25968334
Clin Cancer Res. 2015 Jul 1;21(13):3031-40
pubmed: 25688160
Cancer Res Commun. 2022 Dec 15;2(12):1641-1656
pubmed: 36704666
Front Immunol. 2017 Dec 19;8:1830
pubmed: 29312327
J Pathol. 2018 Jun;245(2):209-221
pubmed: 29603739
Clin Cancer Res. 2014 Apr 15;20(8):2147-58
pubmed: 24523438
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
J Exp Med. 2013 Mar 11;210(3):465-73
pubmed: 23420877
Trends Cancer. 2021 Mar;7(3):214-225
pubmed: 33132107
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33093155
Front Immunol. 2021 Aug 17;12:736670
pubmed: 34484246
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
Immunity. 2005 Nov;23(5):539-50
pubmed: 16286021
Cancer Cell. 2022 Dec 12;40(12):1600-1618.e10
pubmed: 36423635
Cancer Immunol Res. 2017 Nov;5(11):1005-1015
pubmed: 28947544
Cell Rep. 2015 Dec 29;13(12):2687-98
pubmed: 26711337
Oncoimmunology. 2015 Apr 02;4(3):e974374
pubmed: 25949892
Cancer Res. 2011 Sep 1;71(17):5678-87
pubmed: 21846823
Nat Rev Immunol. 2012 Nov;12(11):762-73
pubmed: 23018291